Latest VectorY Therapeutics News & Updates

See the latest news and media coverage for VectorY Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
VectorY Therapeutics

Biotechnology company developing vectorized antibody therapies for neurodegenerative diseases

vectorytx.com
Headquarters
Amsterdam, Netherlands
Founded year
2020
Company type
Private company
Number of employees
100–200

Last updated

Latest news about VectorY Therapeutics

Company announcements

  • VectorY Therapeutics

    VectorY Therapeutics receives MHRA and EMA approvals for PIONEER-ALS trial

    The Phase 1/2 trial of VTx-002 for ALS expands to U.K., Belgium, and Netherlands sites. First U.S. participant dosed.

  • VectorY Therapeutics

    VectorY Therapeutics secures Health Holland Industrial PhD grant

    The grant funds a project with VU Amsterdam on targeting TDP-43 aggregation for ALS and frontotemporal dementia using mass spectrometry. They recruit a PhD candidate.

  • VectorY Therapeutics

    VectorY Therapeutics partners with UnLearnAI

    They utilize patient-level digital twin technology in the PIONEER-ALS study to enhance development decisions, model disease progression, and reduce timelines and participant burden.

  • VectorY Therapeutics

    VectorY Therapeutics doses first participant in PIONEER-ALS trial

    The Phase 1/2 trial evaluates VTx-002, a vectorized antibody targeting TDP-43 in ALS patients. It assesses safety, tolerability, and efficacy across U.S., Europe, and U.K. sites.

Unlock all announcements with a

Media coverage

Unlock all articles with a

Never miss news about VectorY Therapeutics

Track VectorY Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.